Abstract
We aimed to develop a whole genome sequencing (WGS)-based copy number variant (CNV) calling algorithm with the potential of replacing chromosomal microarray assay (CMA) for clinical diagnosis. JAX-CNV is thus developed for CNV detection from WGS. The performance of this CNV calling algorithm was evaluated in a blinded manner on 31 samples and compared to the results of clinically-validated CMAs. Comparing to 112 CNVs reported by clinically-validated CMAs of the 31 samples, JAX-CNV is 100% recalling them. Besides, JAX-CNV identified an average of 30 CNVs per individual that is an approximately seven-fold increase compared to calls of clinically-validated CMAs. Experimental validation of 24 randomly selected CNVs, showed one false positive (i.e., a false discovery rate of 4.17%). A robustness test on lower-coverage data revealed a 100% sensitivity for CNVs greater than 300 kb (the current threshold for College of American Pathologists) down to 10x coverage. For CNVs greater than 50 kb, sensitivities were 100% for coverages deeper than 20x, 97% for 15x, and 95% for 10x. We developed a WGS-based CNV pipeline, including this newly developed CNV caller JAX-CNV, and found it capable of detecting CMA reported CNVs at 100% sensitivity with about 4% false discovery rate. We propose that JAX-CNV could be further examined in a multi-institutional study to justify the transition of first-tier genetic testing from CMAs to WGS. JAX-CNV is available on https://github.com/TheJacksonLaboratory/JAX-CNV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is supported in part by the operational funds from The First Affiliated Hospital of the Xian Jiaotong University. WL was supported by the National Science Foundation of China (61901352) and is supported by National Institute of Health, USA (U24AG041689 and U54AG052427). XY and KY are supported by the National Science Foundation of China (61702406 and 31671372), the National Science and Technology Major Project of China (grant number 2018ZX10302205), the National Key R&D Program of China (2018YFC0910400 and 2017YFC0907500), and the General Financial Grant from the China Postdoctoral Science Foundation (2017M623178). CL was a distinguished Ewha Womans University Professor supported in part by the Ewha Womans University Research grant of 2018-2019.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB Determination Letter Date: September 1, 2017 From: JAX IRB To: CZ Zhang, Ph.D. Re: Development of a whole genome sequencing (WGS)-based platform for detection of deletions/duplications associated with constitutional disorders IRB Reference Number: 17-NHSR-23 Specimen Source: The Coriell Institute for Medical Research ************************************************************************ The Jackson Laboratory (JAX) Institutional Review Board (IRB) has reviewed the submitted Determination of Human Subjects Research form and has determined that this project does not meet the definition of human subjects research under Laboratory policy (POL_RES_06) and applicable Federal Regulations. This research does not involve human subjects since the investigator will not obtain 1) data through intervention or interaction with a living individual or 2) identifiable private information. This determination is based on the fact that samples to be used in this research (deidentified genomic DNA and/or cell lines) will be obtained from The Coriell Institute for Medical Research. If there are any modifications in the research project or study design that could affect the status of this determination, please notify the JAX Institutional Review Board before implementing such change(s). _____________________________________________ Christine Earley, M.A., CIP, IRB Administrator
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the test samples were bought from Coriell Institute and the analysis tool is available on github.
